All articles by Vidya Sagar Maddela
Vidya Sagar Maddela
NICE approves new drug for advanced bowel cancer patients in England and Wales
The drug will be available on the NHS within three months for specific patients with advanced bowel cancer, also known as stage 4 or metastatic bowel cancer, in England and Wales.
Neurizon signs licensing deal with Elanco to commercialise NUZ-001
NUZ-001 is an investigational therapy, currently under development for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases.
Regeneron secures FDA approval for Lynozyfic to treat multiple myeloma
Lynozyfic is a fully human BCMAxCD3 bispecific antibody, indicated for people who have undergone at least four prior lines of therapy.
Sandoz further asserts leadership in biosimilars, breaking ground on new Slovenia facility to expand European biosimilar hub and global market reach
Investment marks latest step in strategic plan to capture significant part of unprecedented biosimilar patent-expiry market opportunity of USD 222 billion over next 10 years.
Jazz secures EC approval for Ziihera to treat HER2-positive BTC
Ziihera is a dual HER2-targeted bispecific antibody that works by binding to extracellular domains 2 and 4 on separate HER2 monomers.
Alvotech, Advanz Pharma expand biosimilar collaboration in Europe
The agreement is centred on AVT10, a biosimilar to Cimzia (certolizumab pegol), a TNF-alpha inhibitor intended to treat various inflammatory diseases.
Fresenius Expands Biosimilars Portfolio With the Availability of Their Denosumab Biosimilars in the U.S.
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively.
BridgeBio raises $300m through Beyonttra royalties monetisation
HealthCare Royalty and Blue Owl Capital provided BridgeBio $300m in exchange for 60% royalties on Beyonttra’s first $500m annual net sales.
Takeda obtains expanded FDA approval for Gammagard Liquid ERC
Gammagard Liquid ERC with IgA content of less than or equal to 2µg/mL in a 10% solution is intended for people with primary immunodeficiency (PI).
Piramal Pharma Solutions Breaks Ground on $90M Expansion Plan
Piramal Pharma Solutions is investing $90M to expand two of its U.S. facilities, adding commercial-scale manufacturing capabilities and significantly enhancing the capacity and efficiency of each site.